新宿・代々木こころのラボクリニック
平日21時まで。

平成22年 American Psychiatric Association Research Colloquium for Junior Investigators

平成24年 American Society of Clinical Psychopharmacology Fellowship Award

平成25年 American Association for Geriatric Psychiatry Early Investigator Poster Award

平成25年 Society of Biological Psychiatry Travel Fellowship Award

平成25年 Asian Clinical Neuropsychophamarcology Travel Fellowship Award

平成26年 American Society of Clinical Psychopharmacology Annual Meeting New Investigator Award

平成26年 University of Toronto’s Best Accomplishment Fellow Award

平成26年 The International College of Geriatric Psychoneuropharmacology Young Investigator Award

平成27年 International Congress on Schizophrenia Research Young Investigator Travel Award

平成27年 American College of Neuropsychopharmacology travel award

平成27年 World Psychiatric Association International Congress Young Psychiatrist Award

平成28年 Schizophrenia International Research Society Conference’s travel award

平成28年 University of Toronto Department of Psychiatry’s Travel Award

平成28年 慶應義塾大学医学部三四会奨励賞

1.Nakajima S, Caravaggio F, Mamo D, Mulsant BH, Chung J, Plitman E, Iwata Y, Gerretsen P, Uchida H, Suzuki T, Mar W, Wilson A, Houle S, Graff-Guerrero A. Dopamine D2/3 Receptor Availability in the Striatum of Antipsychotic-Free Patients with Late-Life Schizophrenia - a cross-sectional [11C]-raclopride PET study. Schizophrenia Research. 2015 May;164(1-3):263-7.

2.Nakajima S, Caravaggio F, Boileau I, Chung J, Plitman E, Gerretsen P, Wilson A, Houle S, Mamo D, Graff-Guerrero A. Lack of Decrease in Dopamine D3 receptor Availability - [11C]-(+)-PHNO and [11C]-Raclopride Positron Emision Tomography Study. Journal of Cerebral Blood Flow & Metabolism. 2015 Nov;35(11):1812-8.

3.Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matsushita K, Chavez S, Sawada S, Wada M, Matsui M, Fujii S, Miyazaki T, Chakravarty MM, Uchida H, Remington G, Graff-Guerrero A, Mimura M, Nakajima S. Levels of Glutamatergic Neurometabolites in Patients with Severe Treatment-Resistant Schizophrenia: A Proton Magnetic Resonance Spectroscopy Study. Neuropsychopharmacology. 2020 Mar;45(4):632-640.

4.Nakajima S, Uchida H, Suzuki T, Watanabe K, Hirano J, Yagihashi T, Takeuchi H, Abe T, Kashima H, Mimura M. Is Switching Antidepressants Following Early Nonresponse More Beneficial in Acute-Phase Treatment of Depression?: A Randomized Open-Label Trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1; 35(8):1983-1989.

5.Iwata Y, Nakajima S, Caravaggio F, Uchida H, Suzuki T, Plitman E, Mar W, Pollock B, Mulsant BH, Rajji TK, Mamo D, Graff-Guerrero A. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients with Schizophrenia. J Clin Psychiatry. 2016 Dec;77(12):e1557-e1563.

6.Nakajima S, Caravaggio F, Mamo D, Mulsant BH, Chung J, Plitman E, Iwata Y, Gerretsen P, Uchida H, Suzuki T, Mar W, Wilson A, Houle S, Graff-Guerrero A. Dopamine D2/3 Receptor Availability in the Striatum of Antipsychotic-Free Patients with Late-Life Schizophrenia - a cross-sectional [11C]-raclopride PET study. Schizophrenia Research. 2015 May;164(1-3):263-7.

7.Nakajima S, Uchida H, Bies R, Caravaggio F, Suzuki T, Plitman E, Mar W, Pollock B, Mulsant B, Mamo D, Graff-Guerrero A. Predicting Dopamine D2 Receptor Occupancy Following Antipsychotic Dose Reduction. Schizophrenia Bulletin. 2016 Jan;42(1):212-9.

8.Graff-Guerrero A, Rajji T, Mulsant B, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock B, Mamo D. Maintenance Antipsychotic Dose Can Be Decreased in Late-life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study with [11C]-raclopride. JAMA Psychiatry. 2015 Sep;72(9):927-34.

9.Nakajima S (co-first), Iwata Y, Suzuki T, Keefe R, Plitman E, Chung J, Caravaggio F, Masaru M, Graff-Guerrero A, Uchida H. Effect of glutamatergic modulators on cognitive impairment in schizophrenia ? systematic review and meta-analysis. Molecular Psychiatry. 2015 Oct;20(10):1151-60.

10.Nakajima S (co-first), Iwata Y, Plitman E, Caravaggio F, Kim J, Shah P, Mar W, Chavez S, De Luca V, Mimura M, Remington G, Gerretsen P, Graff-Guerrero A. Glutamatergic Neurometabolite Levels in Patients with Ultra Treatment-Resistant Schizophrenia: a Cross-sectional 3T Proton MRS study. Biological Psychiatry. 2018 Sep 26.

»もっと見る

平成30年 CINP's(International College of Neuropsychopharmacology) Best Poster Award

平成30年 JSBP's(Japanese Society of Biological Psychiatry) Excellent Presentation Award

令和元年 SOBP's(Society of Biological Psychiatry) Travel Award

令和2年 APA's(American Psychiatric Association) Junior Psychiatrist Investigators Award

1.Wada M, Mimura M, Noda Y, Takasu S, Plitman E, Honda M, Natsubori A, Ogyu K, Tarumi R, Graff-Guerrero A, Nakajima S. Neuroimaging Correlates of Narcolepsy with cataplexy: A Systematic Review. Neurosci Res. 2019 May;142:16-29.

2.Ogyu K, Kubo K, Noda Y, Iwata Y, Tsugawa S, Omura Y, Wada M, Tarumi R, Plitman E, Moriguchi S, Miyazaki T, Uchida H, Graff-Guerrero A, Mimura M, Nakajima S: Kynurenine Pathway in Depression: A Systematic Review and Meta-analysis. Neurosci Biobehav Rev. 2018 Jul;90:16-25.

3.Wada M, Noda Y, Shinagawa S, Chung JK, Sawada K, Ogyu K, Tarumi K, Tsugawa S, Miyazaki T, Yamagata B, Graff-Guerrero A, Mimura M, Nakajima S: Effect of education on Alzheimer’s disease-related neuroimaging biomarkers in healthy controls, and participants with mild cognitive impairment and Alzheimer’s disease - a cross-sectional study. J Alzheimers Dis. 2018;63(2):861-869.

4.Iimori T, Nakajima S, Miyazaki T, Tarumi R, Ogyu K, Wada M, Tsugawa S, Masuda F, Daskalakis ZJ, Blumberger DM, Mimura M, Noda Y. Effectiveness of the prefrontal repetitive transcranial magnetic stimulation on cognitive profiles in depression, schizophrenia, and Alzheimer’s disease: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jan 10;88:31-40.

5.Moriguchi S, Takamiya A, Noda Y, Horita N, Wada M, Tsugawa S, Plitman E, Sano Y, Tarumi R, ElSalhy M, Katayama N, Ogyu K, Miyazaki T, Kishimoto T, Graff-Guerrero A, Meyer JH, Blumberger DM, Daskalakis ZJ, Mimura M, Nakajima S. Glutamatergic Neurometabolite Levels in Major Depressive Disorder: A Systematic Review and Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies. Mol Psychiatry. 2018 Oct 12.

6.Masuda F, Nakajima S, Miyazaki T, Tarumi R, Ogyu K, Wada M, Tsugawa S, Croarkin PE, Mimura M, Noda Y. Clinical effectiveness of repetitive transcranial magnetic stimulation treatment in children and adolescents with neurodevelopmental disorders: A systematic review. Autism. 2019 Jan 20:1362361318822502.

7.Masuda F, Nakajima S, Miyazaki T, Yoshida K, Tsugawa S, Wada M, Ogyu K, Croarkin PE, Blumberger DM, Daskalakis ZJ, Mimura M, Noda Y. Motor cortex excitability and inhibitory imbalance in autism spectrum disorder assessed with transcranial magnetic stimulation: a systematic review. Transl Psychiatry. 2019 Mar 7;9(1):110.

8.Wada M, Kurose S, Miyazaki T, Nakajima S, Masuda F, Mimura Y, Nishida H, Ogyu K, Tsugawa S, Mashima Y, Plitman E, Chakravarty MM, Mimura M, Noda Y. The P300 event-related potential in bipolar disorder: A systematic review and meta-analysis. J Affect Disord. 2019 Jun 4;256:234-249.

9.Noda Y, Barr MS, ElSalhy M, Masuda F, Tarumi R, Ogyu K, Wada M, Tsugawa S, Miyazaki T, Nakajima S, Mimura M. Neural correlates of delay discount alterations in addiction and psychiatric disorders: A systematic review of magnetic resonance imaging studies. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Nov 18:109822.

10.Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matsushita K, Chavez S, Sawada K, Wada M, Matsui M, Fujii S, Miyazaki T, Chakravarty MM, Uchida H, Remington G, Graff-Guerrero A, Mimura M, Nakajima S. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology. 2019 Dec 16. doi: 10.1038/s41386-019-0589-z.

1.Yoshida K, Mimura Y, Ishihara R, Nishida H, Komaki Y, Minakuchi T, Tsurugizawa T, Mimura M, Okano H, Tanaka KF, Takata N. Physiological effects of a habituation procedure for functional MRI in awake mice using a cryogenic radiofrequency probe. J Neurosci Methods. 2016 Dec 1;274:38-48.

2.三村 悠, 荻野 聡之, 高田 武人, 三村 将, 船山 道隆. 麻痺性イレウスを契機とした低カリウム血症加療中にたこつぼ型心筋症を合併した統合失調症の一例 -統合失調症と腸管- 栃木精神医学 第38 巻（2018) 32 - 39 頁.

3.Takashin Nakayama, Yu Mimura, Keita Hirano. Renal cortical hypoperfusion caused by glyphosate surfactant herbicide. Clin Exp Nephrol. 2019 Jan 19.

4.三村悠：摂食障害と神経心理学的所見. 神経心理学：35（4），207─214，2019.

5.S Kurose, Y Mimura, H Uchida, K Takahata, E Kim, T Suzuki, M Mimura, H Takeuchi: Dissociation in Pharmacokinetic Attenuation between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic review. Journal of Clinical Psychiatry. J Clin Psychiatry 2020;81(5):19r13113.

6.Mimura Y, Funayama M, Oi H1, Takata T, Takeuchi H, Mimura M. Effectiveness of Brexpiprazole in the Treatment in a Patient with Huntington's Disease. Psychiatry Clin Neurosci. 2020 Jan 13.

7. Yu Mimura, Shin Kurose, Taketo Takata, Hajime Tabuchi, Masaru Mimura and Michitaka Funayama. Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report. BMC Neurology (2020) 20:183.

8. Michitaka Funayama; Yu Mimura, M.D.; Taketo Takata, M.D.; Akihiro Koreki, M.D., Ph.D; Satoyuki Ogino, M.D.; Shin Kurose, M.D. Body mass index and blood urea nitrogen to creatinine ratio predicts refeeding hypophosphatemia of anorexia nervosa patients with severe malnutrition. Journal of Eating Disorders. 2021 Jan 6;9(1):1.

9. Mimura Y, Nishida H, Nakajima S*, Tsugawa S, Morita S, Yoshida K, Tarumi R, Ogyu K, Wada M, Kurose S, Miyazaki T, Blumberger DM, Daskalakis ZJ, Chen R, Mimura M, Noda Y*, Neurophysiological biomarkers using transcranial magnetic stimulation in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2021 Feb;121:47-59.

10. Mimura Y, Shimizu Y, Oi H, Kurose S, Kudo S, Takata T, Mimura M, and Funayama M. “Case Series: Ischemic stroke associated with dehydration and arteriosclerosis in individuals with severe anorexia nervosa.” Journal of Eating Disorders, 2021 Mar 20;9(1):39.

平成28年 NARSAD Young Investigator Award

平成29年 米国核医学会・Wagner-Torizuka Fellowship Award

平成29年 Clinical Trials Fellowship Award by the American Society of Clinical Psychopharmacology

平成29年 Society of Biological Psychiatry Travel Fellowship Award

平成29年 米国核医学会・Alavi-mandell Award

平成30年 日本精神神経学会・精神医学奨励賞

令和3年 日本うつ病学会・学会奨励賞

1.Moriguchi S, Takahata K, Shimada H, Kubota M, Kitamura S, Kimura Y, Tagai K, Tarumi R, Tabuchi H, Meyer JH, Mimura M, Kawamura K, Zhang MR, Murayama S, Suhara T, Higuchi M. Excess tau PET ligand retention in elderly patients with major depressive disorder: a PET study.
Mol Psychiatry. 2020; doi: 10.1038/s41380-020-0766-9. Online ahead of print.

2.Kubota M, Moriguchi S, Takahata K, Nakajima S, Horita N. Treatment effects on neurometabolite levels in schizophrenia: A systematic review and meta-analysis of proton magnetic resonance spectroscopy studies.
Schizophr Res. 2020 Aug; 222:122-132. doi: 10.1016/j.schres.2020.03.069.

3.Takahata K, Kimura Y, Sahara N, Koga S, Shimada H, Ichise M, Saito F, Moriguchi S, Kitamura S, Kubota M, Umeda S, Niwa F, Mizushima J, Morimoto Y, Funayama M, Tabuchi H, Bieniek KF, Kawamura K, Zhang MR, Dickson DW, Mimura M, Kato M, Suhara T, Higuchi M. PET-detectable Tau Pathology Correlates With Long-Term Neuropsychiatric Outcomes in Patients With Traumatic Brain Injury.
Brain. 2019 Oct;142(10):3265-3279.

4.Moriguchi S, Wilson AA, Miler L, Rusjan PM, Vasdev N, Kish SJ, Rajkowska G, Wang J, Bagby M, Mizrahi R, Varughese B, Houle S, Meyer JH. Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder: An [11C]SL25.1188 Positron Emission Tomography Study.
JAMA Psychiatry. 2019 Jun;76(6):634-641.

5.Moriguchi S, Takamiya A, Noda Y, Horita N, Wada M, Tsugawa S, Plitman E, Sano Y, Tarumi R, ElSalhy M, Katayama N, Ogyu K, Miyazaki T, Kishimoto T, Graff-Guerrero A, Meyer JH, Blumberger DM, Daskalakis ZJ, Mimura M, Nakajima S. Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies.
Mol Psychiatry. 2018 Jul;24(7):952-964.

6.Ogyu K, Kubo K, Noda Y, Iwata Y, Tsugawa S, Omura Y, Wada M, Tarumi R, Plitman E, Moriguchi S, Miyazaki T, Uchida H, Graff-Guerrero A, Mimura M, Nakajima S. Kynurenine pathway in depression: A systematic review and meta-analysis.
Neurosci Biobehav Rev. 2018; 90:16-25.

7.Ishii T, Kimura Y, Ichise M, Takahata K, Kitamura S, Moriguchi S, Kubota M, Zhang MR, Yamada M, Higuchi M, Okubo Y, Suhara T. Anatomical relationships between serotonin 5-HT2A and dopamine D2 receptors in living human brain.
PLoS One. 2017; 12(12):e0189318.

8.Moriguchi S, Takano H, Kimura Y, Nagashima T, Takahata K, Kubota M, Kitamura S, Ishii T, Ichise M, Zhang MR, Shimada H, Mimura M, Meyer JH, Higuchi M, Suhara T. Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2.
Int J Neuropsychopharmacol. 2017; 20(12):957-962.

9.Kubota M, Nagashima T, Takano H, Kodaka F, Fujiwara H, Takahata K, Moriguchi S, Kimura Y, Higuchi M, Okubo Y, Takahashi H, Ito H, Suhara T. Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia.
Int J Neuropsychopharmacol. 2017; 20(11):928-935.

10.Takahata K, Kimura Y, Seki C, Tokunaga M, Ichise M, Kawamura K, Ono M, Kitamura S, Kubota M, Moriguchi S, Ishii T, Takado Y, Niwa F, Endo H, Nagashima T, Ikoma Y, Zhang MR, Suhara T, Higuchi M. A human PET study of [11C]HMS011, a potential radioligand for AMPA receptors.
EJNMMI Res. 2017; 7: 63.

11.Moriguchi S, Ichise M, Kimura Y, Takahata K, Mimura M, Yamada M, Suhara T. New quantification method of Norepinephrine transporter in the cortex area in human brain with (S,S)-[18F]FMeNER-D2.
J Nucl Med. 2017; 58:1140-1145.

12.12. Moriguchi S, Yamada M, Takano H, Nagashima T, Takahata K, Yokokawa K, Ito T, Ishii T, Kimura Y, Zhang MR, Mimura M, Suhara T. Norepinephrine Transporter in Major Depressive Disorder; A PET study.
Am J Psychiatry. 2017; 174:36-41.

13.13. Kimura Y, Seki C, Ikoma Y, Ichise M, Kawamura K, Takahata K, Moriguchi S, Nagashima T, Ishii T, Kitamura S, Niwa F, Endo H, Yamada M, Higuchi M, Zhang M, Suhara T. [11C]TASP457, A Novel PET Ligand for Histamine H3 Receptors in Human Brain.
Eur J Nucl Med Mol Imaging. 2015; 43:1653-63.

14.Kocha H, Moriguchi S, Mimura M. Revisiting the Concept of Late Catatonia.
Compr Psychiatry. 2014; 55: 1485-1490.

15.15. Moriguchi S, Bies R, Remington G, Suzuki T, Mamo D, Watanabe K, Mimura M, Pollock B, Uchida H. Estimated Dopamine D2 Receptor Occupancy and Remission in Schizophrenia: Analysis of the CATIE Data.
J Clin Psychopharmacol. 2013; 33: 682-685.